Cancer/Tumor Profiling Market – Global Industry Analysis and Forecast (2017-2026) _ by Technology (Immunoassay, Hybridization, NGS, Mass Spectrometry and Others), by Cancer Type (Breast, Lung, Prostate and Others), by Application and by Geography

Cancer/Tumor Profiling Market – Global Industry Analysis and Forecast (2017-2026) _ by Technology (Immunoassay, Hybridization, NGS, Mass Spectrometry and Others), by Cancer Type (Breast, Lung, Prostate and Others), by Application and by Geography

Market Scenario

Cancer/Tumor Profiling Market is expected to reach USD 14.02 Billion by 2026 from USD 4.92 Billion in 2016 at a CAGR of 11.04% (Detailed analysis of the market CAGR is provided in the report). A tumor profiling test gives information about the genes in cancer cells. Cancer-Tumor Profiling Market Cancer/tumor profiling market based on technology is broadly classified into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. The immunoassays segment is expected to hold one of the largest shares of cancer/tumor profiling market. The high sensitivity and cost-effectiveness of these techniques and technological improvements in these immunoassays tests are some factors expected to drive the growth of this market during the forecast period. Cancer/tumor profiling market based on cancer type has been divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancer types. The breast cancer segment is expected to be one of the major contributors for the market and grow at a high CAGR during the forecast period. The growth of this segment is mainly attributed to the high incidence of breast cancer over the last few years and increasing awareness about breast cancer among the population. Geographically, North America is projected to be one of the largest markets for cancer/tumor profiling and Asia Pacific (APAC) is expected to witness the highest growth during the forecast period. An increasing prevalence of cancer and rising demand for better healthcare services across developing countries such as India and China and increasing utility of biomarkers in tumor profiling and large funding for cancer research are the factors driving the market growth. The years that have been considered for the market analysis are: • Base year – 2016 • Estimated year – 2017 • Forecast period – 2016 to 2026 Key Highlights: • Cancer profiling market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the cancer profiling market. • Cancer profiling market segmentation on the basic application, technology, cancer type and geography (country-wise) has been provided. • Cancer profiling market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of the study. • Cancer profiling market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the cancer profiling market are also profiled. Research Methodology: The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get unbiased idea of the market. This exercise was done at country level to get fair idea of the market in countries considered for this study. Later this country specific data was accumulated to come up with regional numbers and then arrive at global market value for Cancer profiling market.   The key players operating in the cancer profiling market include: • Illumina (US) • NeoGenomics Laboratories (US) • QIAGEN (Netherlands) • Genomic Health (US) • HTG Molecular Diagnostic (US) • Oxford Gene Technology (UK) • Helomics Corporation (US) • Caris Life Sciences (US) • NanoString Technologies (US) • RiboMed Biotechnologies (US). Key Target Audience: • Hospitals and clinics • Authorities framing reimbursement policies for use of cancer diagnostics • Companies offering platforms or technologies for cancer diagnosis • Authorities framing reimbursement policies for use of cancer diagnostics • Market research and consulting firms

Scope of the Cancer Profiling Market Report

The Research report segments the cancer profiling market based on application, technology, cancer type and geography

Cancer Profiling Market, by Application:

• Clinical Applications • Research Applications

Cancer Profiling Market, by Technology:

• Immunoassays • Hybridization • Next-generation Sequencing • Mass Spectroscopy • Other Technologies

Cancer Profiling Market, by Cancer Type:

• Breast Cancer • Lung Cancer • Colorectal Cancer • Prostate Cancer • Melanoma Cancer • Other Cancer Types

Cancer Profiling Market, by Geography:

• North America • Europe • Asia Pacific • Middle East & Africa • Latin America Geographic Analysis • Breakdown of North America Cancer Profiling Market • Breakdown of Europe Cancer Profiling Market • Breakdown of Asia Pacific Cancer Profiling Market • Breakdown of Middle East & Africa Cancer Profiling Market • Breakdown of Latin America Cancer Profiling Market Available Customization Maximize Market Research offers customization of reports according to the specific requirement of our clients Peripheral Vascular Devices Market

Table of Contents

Cancer Profiling Market

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. END-USER OVERVIEW 4.1. Value Chain Analysis 4.2. Key Trends 5. CANCER/TUMOR PROFILING MARKET, BY APPLICATION (2016-2026) 5.1. Introduction 5.2. Cancer/Tumor Profiling Market, by Clinical Application 5.2.1. Clinical Application Market Overview 5.2.2. Clinical Application Market Size & Forecast 5.3. Cancer/Tumor Profiling Market, by Research Application 5.3.1. Research Application Market Overview 5.3.2. Research Application Market Size & Forecast 6. CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (2016-2026) 6.1. Introduction 6.2. Cancer/Tumor Profiling Market, by Immunoassays 6.2.1. Immunoassays Market Overview 6.2.2. Immunoassays Market Size & Forecast 6.3. Cancer/Tumor Profiling Market, by Hybridization 6.3.1. Hybridization Market Overview 6.3.2. Hybridization Market Size & Forecast 6.3.2.1. PCR 6.3.2.2. In Situ Hybridization (ISH) 6.3.2.3. DNA/RNA Microarray 6.4. Cancer/Tumor Profiling Market, by Next Generation Sequencing 6.4.1. Next Generation Sequencing Market Overview 6.4.2. Next Generation Sequencing Market Size & Forecast 6.5. Cancer/Tumor Profiling Market, by Mass Spectrometry 6.5.1. Mass Spectrometry Market Overview 6.5.2. Mass Spectrometry Market Size & Forecast 6.6. Cancer/Tumor Profiling Market, by Other Technologies 6.6.1. Other Technologies Market Overview 6.6.2. Other Technologies Market Size & Forecast 7. CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE (2016-2026) 7.1. Introduction 7.2. Cancer/Tumor Profiling Market, by Breast Cancer 7.2.1. Breast Cancer Market Overview 7.2.2. Breast Cancer Market Size & Forecast 7.3. Cancer/Tumor Profiling Market, by Lung Cancer 7.3.1. Lung Cancer Market Overview 7.3.2. Lung Cancer Market Size & Forecast 7.4. Cancer/Tumor Profiling Market, by Colorectal Cancer 7.4.1. Colorectal Cancer Market Overview 7.4.2. Colorectal Cancer Market Size & Forecast 7.5. Cancer/Tumor Profiling Market, by Prostate Cancer 7.5.1. Prostate Cancer Market Overview 7.5.2. Prostate Cancer Market Size & Forecast 7.6. Cancer/Tumor Profiling Market, by Melanoma Cancer 7.6.1. Melanoma Cancer Market Overview 7.6.2. Melanoma Cancer Market Size & Forecast 7.7. Cancer/Tumor Profiling Market, by Others Cancer 7.7.1. Others Cancer Market Overview 7.7.2. Others Cancer Market Size & Forecast 8. CANCER/TUMOR PROFILING MARKET, BY GEOGRAPHY (2016-2026) 8.1. North America Cancer/Tumor Profiling Market 8.1.1. North America Cancer/Tumor Profiling Market, by Application 8.1.2. North America Cancer/Tumor Profiling Market, by Technology 8.1.3. North America Cancer/Tumor Profiling Market, by Cancer Type 8.1.4. North America Cancer/Tumor Profiling Market, by Region 8.1.4.1. U.S. Cancer/Tumor Profiling Market 8.1.4.2. Canada Cancer/Tumor Profiling Market 8.1.4.3. Rest of North America Cancer/Tumor Profiling Market 8.2. Europe Cancer/Tumor Profiling Market 8.2.1. Europe Cancer/Tumor Profiling Market, by Application 8.2.2. Europe Cancer/Tumor Profiling Market, by Technology 8.2.3. Europe Cancer/Tumor Profiling Market, by Cancer Type 8.2.4. Europe Cancer/Tumor Profiling Market, by Region 8.2.4.1. France Cancer/Tumor Profiling Market 8.2.4.2. Germany Cancer/Tumor Profiling Market 8.2.4.3. U.K .Cancer/Tumor Profiling Market 8.2.4.4. Rest of Europe Cancer/Tumor Profiling Market 8.3. Asia Pacific Cancer/Tumor Profiling Market 8.3.1. Asia-Pacific Cancer/Tumor Profiling Market, by Application 8.3.2. Asia-Pacific Cancer/Tumor Profiling Market, by Technology 8.3.3. Asia-Pacific Cancer/Tumor Profiling Market, by Cancer Type 8.3.4. Asia-Pacific Cancer/Tumor Profiling Market, by Region 8.3.4.1. China Cancer/Tumor Profiling Market 8.3.4.2. Japan Cancer/Tumor Profiling Market 8.3.4.3. India Cancer/Tumor Profiling Market 8.3.4.4. Australia Cancer/Tumor Profiling Market 8.3.4.5. South Korea Cancer/Tumor Profiling Market 8.3.4.6. Rest of Asia Pacific Cancer/Tumor Profiling Market 8.4. Middle East & Africa Cancer/Tumor Profiling Market 8.4.1. Middle East & Africa Cancer/Tumor Profiling Market, by Application 8.4.2. Middle East & Africa Cancer/Tumor Profiling Market, by Technology 8.4.3. Middle East & Africa Cancer/Tumor Profiling Market, by Cancer Type 8.4.4. Middle East & Africa Cancer/Tumor Profiling Market, by Region 8.4.4.1. South Africa Cancer/Tumor Profiling Market 8.4.4.2. Egypt Cancer/Tumor Profiling Market 8.4.4.3. Nigeria Cancer/Tumor Profiling Market 8.4.4.4. Rest of Middle East & Africa Cancer/Tumor Profiling Market 8.5. Latin America Cancer/Tumor Profiling Market 8.5.1. Latin America Cancer/Tumor Profiling Market, by Application 8.5.2. Latin America Cancer/Tumor Profiling Market, by Technology 8.5.3. Latin America Cancer/Tumor Profiling Market, by Cancer Type 8.5.4. Latin America Cancer/Tumor Profiling Market, by Region 8.5.4.1. Brazil Cancer/Tumor Profiling Market 8.5.4.2. Argentina Cancer/Tumor Profiling Market 8.5.4.3. Columbia Cancer/Tumor Profiling Market 8.5.4.4. Mexico Cancer/Tumor Profiling Market 8.5.4.5. Rest of Latin America Cancer/Tumor Profiling Market 9. MARKET COMPETITION ANALYSIS 9.1 Market Share/Positioning Analysis 9.2 Key Innovators 9.3 Company Profiles 9.3.1 Illumina, Inc. 9.3.1.1 Overview 9.3.1.2 Products/ End-User 9.3.1.3 Strategy 9.3.1.4 Key Developments 9.3.2 Neogenomics Laboratories, Inc. 9.3.2.1 Overview 9.3.2.2 Products/ End-User 9.3.2.3 Strategy 9.3.2.4 Key Developments 9.3.3 Qiagen N.V. 9.3.3.1 Overview 9.3.3.2 Products/ End-User 9.3.3.3 Strategy 9.3.3.4 Key Developments 9.3.4 HTG Molecular Diagnostics, Inc. 9.3.4.1 Overview 9.3.4.2 Products/ End-User 9.3.4.3 Strategy 9.3.4.4 Key Developments 9.3.5 Caris Life Sciences 9.3.5.1 Overview 9.3.5.2 Products/ End-User 9.3.5.3 Strategy 9.3.5.4 Key Developments 9.3.6 Genomic Health Inc. 9.3.6.1 Overview 9.3.6.2 Products/ End-User 9.3.6.3 Strategy 9.3.6.4 Key Developments 9.3.7 Helomics Corporation 9.3.7.1 Overview 9.3.7.2 Products/ End-User 9.3.7.3 Strategy 9.3.7.4 Key Developments 9.3.8 Oxford Gene Technology 9.3.8.1 Overview 9.3.8.2 Products/ End-User 9.3.8.3 Strategy 9.3.8.4 Key Developments 9.3.9 Nanostring Technologies, Inc. 9.3.9.1 Overview 9.3.9.2 Products/ End-User 9.3.9.3 Strategy 9.3.9.4 Key Developments 9.3.10 Ribomed Biotechnologies, Inc. 9.3.10.1 Overview 9.3.10.2 Products/ End-User 9.3.10.3 Strategy 9.3.10.4 Key Developments LIST OF TABLES Table 1 List of Fda-Approved Biomarkers for Different Types of Cancer Table 2 National Institutes of Health (NIH) Spending, By Type of Cancer (Financial Year 2016) Table 3 Cancer/Tumor Profiling Market Size, By Technology, 2016–2026 (USD Million) Table 4 Hybridization Market for Cancer/Tumor Profiling, By Technology, 2016–2026 (USD Million) Table 5 Global Immunoassays Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 6 North America: Immunoassays Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 7 Global Hybridization Market for Cancer/Tumor Profiling, By Region, 2016-2026 (USD Million) Table 8 North America: Hybridization Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 9 Global PCR Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 10 North America: PCR Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 11 Global In Situ Hybridization Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 12 North America: In Situ Hybridization Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 13 Global DNA/RNA Microarray Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 14 North America: DNA/RNA Microarray Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 15 Global Next-Generation Sequencing Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 16 North America: Next-Generation Sequencing Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 17 Global Mass Spectrometry Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 18 North America: Mass Spectrometry Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 19 Global Other Technologies Market for Cancer/Tumor Profiling, By Region, 2016–2026 (USD Million) Table 20 North America: Other Technologies Market for Cancer/Tumor Profiling, By Country, 2016–2026 (USD Million) Table 21 Global Cancer Profiling Market Size, By Cancer Type, 2016–2026 (USD Million) Table 22 Global Breast Cancer Profiling Market Size, By Region, 2016–2026 (USD Million) Table 23 North America Breast Cancer Profiling Market, By Country, 2016–2026 (USD Million) Table 24 Global Lung Cancer Profiling Market, By Region, 2016–2026 (USD Million) Table 25 North America Lung Cancer Profiling Market, By Country, 2016–2026 (USD Million) Table 26 Global Colorectal Cancer Profiling Market, By Region, 2016–2026 (USD Million) Table 27 North America Colorectal Cancer Profiling Market, By Country, 2016–2026 (USD Million) Table 28 Global Prostate Cancer Profiling Market, By Region, 2016–2026 (USD Million) Table 29 Global Melanom Cancer Profiling Market, By Region, 2016–2026 (USD Million) Table 30 North America Melanoma Cancer Profiling Market, By Country, 2016–2026 (USD Million) Table 31 Global Other Type of Cancer Profiling Market, By Region, 2016–2026 (USD Million) Table 32 North America Other Type of Cancer Profiling Market By Country, 2016–2026 (USD Million) Table 33 Cancer/Tumor Profiling Market Size, By Application, 2016–2026 (USD Million) Table 34 Cancer Profiling Market for Clinical Application, By Region, 2016–2026 (USD Million) Table 35 North America: Cancer/Tumor Profiling Market for Clinical Application, By Region, 2016–2026 (USD Million) Table 36 Cancer Profiling Market for Resaerch Application, By Region, 2016–2026 (USD Million) Table 37 North America: Cancer/Tumor Profiling Market for Resaerch Application, By Region, 2016–2026 (USD Million) Table 38 Global Cancer Profiling Market, By Region, 2016–2026 (USD Million) Table 39 North America: Cancer Profiling Market Size, By Country, 2016–2026 (USD Million) Table 40 North America: Market Size, By Cancer Type, 2016–2026 (USD Million) Table 41 North America: Market, By Technology, 2016–2026 (USD Million) Table 42 North America: Hybridization Technology Market, By Type, 2016–2026 (USD Million) Table 43 North America: Market, By Application, 2016–2026 (USD Million) Table 44 US: Cancer Profiling Market, By Technology, 2016–2026 (USD Million) Table 45 US: Hybridization Technology Market, By Type, 2016–2026 (USD Million) Table 46 US: Market, By Application, 2016–2026 (USD Million) Table 47 US: Cancer Profiling Market, By Cancer Type, 2016–2026 (USD Million) Table 48 Canada: Cancer Profiling Market, By Technology, 2016–2026 (USD Million) Table 49 Canada: Hybridization Technology Market, By Type, 2016–2026 (USD Million) Table 50 Canada: Market, By Application, 2016–2026 (USD Million) Table 51 Canada: Market, By Cancer Type, 2016–2026 (USD Million) Table 52 Europe: Cancer Profiling Market, By Cancer Type, 2016–2026 (USD Million) Table 53 Europe: Market, By Technology, 2016–2026 (USD Million) Table 54 Europe: Hybridization Technology Market, By Type, 2016–2026 (USD Million) Table 55 Europe: Market, By Application, 2016–2026 (USD Million) Table 56 Asia-Pacific: Cancer Profiling Market, By Cancer Type, 2016–2026 (USD Million) Table 57 Asia-Pacific: Cancer Profiling Market, By Technology, 2016–2026 (USD Million) Table 58 Asia-Pacific: Hybridization Technology Market, By Type, 2016–2026 (USD Million) Table 59 Asia-Pacific: Market, By Application, 2016–2026 (USD Million) Table 60 RoW: Cancer Profiling Market, By Cancer Type, 2016–2026 (USD Million) Table 61 RoW: Cancer Profiling Market, By Technology, 2016–2026 (USD Million) Table 62 RoW: Hybridization Technology Market, By Type, 2016–2026 (USD Million) Table 63 RoW: Cancer Profiling Market, By Application, 2016–2026 (USD Million) Table 64 Product Launches, 2015–2016 Table 65 Agreements, Collaborations, and Partnerships, 2015–2016 Table 66 Acquisitions, 2015–2016 Table 67 Other Strategies, 2015–2016 LIST OF FIGURES Figure 1 Research Design Figure 2 Cancer/Tumor Profiling Market Top Down Approach Figure 3 Cancer Profiling Market: Bottom Up Approach Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region Figure 5 Market Data Triangulation Methodology Figure 6 Healthcare Expenditure Across Major Countries: 2015 vs. 2016 Figure 7 Cancer/Tumor Profiling Market, By Cancer Type, 2016 vs. 2026 (USD Million) Figure 8 Cancer Profiling Market, By Technology, 2016 vs. 2026 (USD Million) Figure 9 Cancer/Tumor Profiling Market, By Hybridization Technology, 2016 vs. 2026 (USD Million) Figure 10 Cancer Profiling Market, By Application, 2016 vs. 2026 (USD Million) Figure 11 Geographical Snapshot of the Cancer/Tumor Profiling Market Figure 12 Technology Advancement is A Major Driver for the Cancer Profiling Market Growth in 2016 Figure 13 Clinical Application Will Continue to Dominate the Cancer Profiling Market in 2026 Figure 14 PCR is Expected to Be the Fastest Growing Segment During Forecast Period Figure 15 APAC Will Be the Fastest-Growing Market From 2016 to 2026 Figure 16 Cancer/Tumor Profiling Market: Drivers, Restraints, Opportunities, and Challenges Figure 17 Increasing Number of New Cancer Cases Worldwide, 2016 vs. 2026 Figure 18 New Cancer Cases, By Country, 2016 Figure 19 New Cancer Cases, By Country, 2026 Figure 20 Immunoassays Segment to Dominate the Market in the Forecast Period Figure 21 Clinical Application Segment to Dominate the Market in the Forecast Period Figure 22 Cancer Profiling Market: Geographic Snapshot, 2016–2026 Figure 23 North America Market Snapshot Figure 24 Asia-Pacific Cancer Profiling Market Snapshot Figure 25 Companies Majorly Pursued the Strategy of Product Launch Between 2016 and 2026 Figure 26 Geographic Revenue Mix of the Prominent Players in the Cancer Profiling Market Figure 27 Company Snapshot: Illumina, Inc. Figure 28 Company Snapshot: Qiagen N.V. Figure 29 Company Snapshot: Neogenomics Laboratories, Inc. Figure 30 Company Snapshot: HTG Molecular Diagnostics, Inc. Figure 31 Company Snapshot: Genomic Health Inc. Figure 32 Company Snapshot: Nanostring Technologies, Inc.

Inquiry Before Buying

Request Sample

About This Report

Report ID 1392
Published Date
Contact Us
Call Now